( MENAFN - GetNews) . Developing Therapeutics for the treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD. .
June Meeting of the American Society for Clinical Psychopharmacology Focused on Intravenous Ketamine and Intranasal S-Ketamine for Severe Depression and Suicidality. . Presenters from 3 Open Label Studies at the ASCP Suggested Intravenous Ketamine is Equivalent or has Advantages over Intranasal S-Ketamine.
. NRXP Reached 9-Month Stability Point with its Ketamine Formulation (NRX-100) and Initiated 3 Manufacturing Lots for Future Drug Release. .
Nonclinical Safety for Short Term Use of NRX-100 Recently Published and Submitted to FDA. . FDA Leadership, in Public Comments at ASCP, Focused on the Need for Nonclinical Safety Data for Intravenous Ketamine as a Condition of Approval.
. Short-Term Need for Intravenous Ketamine as an Already-Approved, Schedule 3 Drug Heightened by Recent Decisions that May Delay Schedule 1 Psychedelics. .
MOU Signed with Conversio Health with Immediate Plans to Ship IV Ketamine Product to Full Range of Customers via 503a and 503b Pharmacies. . Clinical Trial Success in Proving a Statistically-Significant 76% Reduction in Akathisia in Participants Treated with NRX-101 Compared to Lurasidone.
. Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRXP Shareholders. .
Received $5 Million Milestone Payment from Partners Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.
.
